More on TAK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $18.21 |
|
|||
| Open | $18.34 | ||||
| 52 Wk High | $0.55 | ||||
| 52 Wk Low | $0.55 | ||||
| Day High | $18.34 | ||||
| Day Low | $18.10 | ||||
| P/E | N/A | ||||
| EPS | $-0.20 | ||||
| Volume | 1,749,287 | ||||
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
- NEJM publishes Takeda's phase 3 data on narcolepsy drug oveporexton
- New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
- Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,300 at Morgan Stanley
- Form 4 TAKEDA PHARMACEUTICAL For: Sep 02 Filed by: Plump Andrew Stewart
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
- Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Nomura/Instinet
- Form 6-K TAKEDA PHARMACEUTICAL For: Aug 28
- FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
- Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Entities mentioned with TAK
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Dividend | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
